HISTOCHEMICAL DISTRIBUTION OF CA-125 AS A PROGNOSTIC INDICATOR IN PATIENTS WITH SEROUS OVARIAN-CANCER

被引:3
作者
BICHEL, P
JAKOBSEN, A
ORNTOFT, TF
机构
[1] AARHUS UNIV, AARHUS KOMMUNE HOSP, INST PATHOL, DEPT CLIN CHEM, DK-8000 AARHUS, DENMARK
[2] VEJLE CENT HOSP, INST PATHOL, AARHUS, DENMARK
[3] DANISH CANC SOC, DEPT EXPTL CLIN ONCOL, AARHUS, DENMARK
关键词
CA-125; HISTOCHEMICAL DISTRIBUTION; OVARY CARCINOMA; PROGNOSIS;
D O I
10.1111/j.1525-1438.1991.tb00040.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The study comprises 66 patients with stage Ill and IV serous ovarian carcinoma While the percentage of CA-125 positive cells and the staining intensity showed no correlation to patient survival, the pattern of CA-125 distribution, membranous versus cytoplasmic, was significantly correlated to survival. In accordance with other observations on switching of the antigen reaction f rom membrane to cytoplasm with increasing grade of atypia or malignancy, patients with membrane positive CA-125 tumors had a significantly better prognosis than did patients with CA-125 in the cytoplasm. Furthermore, there was excellent agreement between, on the one hand, the binding pattern of CA-125 and, on the other, the ploidy of the tumor cells and the HGI histopathologic grading index, both previously shown to be of prognostic significance.
引用
收藏
页码:199 / 204
页数:6
相关论文
共 50 条
  • [41] The Diagnostic Value of Serum CEA, CA-125, and ROMA Index in Low-Grade Serous Ovarian Cancer
    Bashizadeh-Fakhar, Haniyeh
    Rezaie-Tavirani, Mostafa
    Zali, Hakimeh
    Faraji, Roya
    Nejad, Ehsan Kazem
    Aghazadeh, Mohamadhossein
    INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2018, 11 (05)
  • [42] Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis
    Metzler, Julian Matthias
    Fink, Daniel
    Imesch, Patrick
    APPLIED SCIENCES-BASEL, 2021, 11 (01): : 1 - 6
  • [43] Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer
    Xu, Jian-Lun
    Commins, John
    Partridge, Edward
    Riley, Thomas L.
    Prorok, Philip C.
    Johnson, Christine C.
    Buys, Saundra S.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (01) : 70 - 74
  • [44] CA-125 AUC as a predictor for epithelial ovarian cancer relapse
    Manoa, Antonio
    Falcao, Amilcar
    Godinho, Isabel
    Santos, Jorge
    Leitao, Fatima
    de Oliveira, Carlos
    Caramona, Margarida
    CANCER BIOMARKERS, 2008, 4 (02) : 73 - 81
  • [45] Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis
    Wang, Qingyi
    Feng, Xiaoling
    Liu, Xiaofang
    Zhu, Siyu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [46] The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer
    Hogdall, CK
    Norgaard-Pedersen, B
    Mogensen, O
    ANTICANCER RESEARCH, 2002, 22 (03) : 1765 - 1768
  • [47] Ovarian cancer patients with high CA-125 but no symptoms should antiangiogenic treatments be considered?
    Sharma, A
    Bernacki, RJ
    ONCOLOGY RESEARCH, 1997, 9 (02) : 53 - 54
  • [48] Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer
    Kolwijck, Eva
    Span, Paul N.
    Thomas, Chris M. G.
    Bulten, Johan
    Sweep, Fred C. G. J.
    Massuger, Leon F. A. G.
    ONCOLOGY REPORTS, 2010, 23 (02) : 579 - 584
  • [49] Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction
    Mahner, Sven
    Woelber, Linn
    Jung, Sabine
    Eulenburg, Christine Zu
    Ihnen, Maike
    Schwarz, Joerg
    Sehouli, Jalid
    Jaenicke, Fritz
    ANTICANCER RESEARCH, 2009, 29 (07) : 2817 - 2821
  • [50] Prognostic and predictive value of combined HE-4 and CA-125 biomarkers during chemotherapy in patients with epithelial ovarian cancer
    Potenza, Enrico
    Parpinel, Giulia
    Laudani, Maria E.
    Macchi, Chiara
    Fuso, Luca
    Zola, Paolo
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2020, 35 (04) : 20 - 27